

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Bepirovirsen for treating chronic hepatitis B ID6608

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • GSK (bepirovirsen) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Addiction Recovery Agency • African Health Policy Network (AHPN) • Black Health Agency for Equality • British Liver Trust • Chinese National Healthy Living Centre • Compass UK • Hepatitis B Foundation UK • HIV i-Base • Liver4Life • LIVERnORTH • LGBT Hero • National AIDS Trust • Positively UK • Release • South Asian Health Foundation • Specialised Healthcare Alliance • Terrence Higgins Trust • The Mix • We Are With You <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • British Association for Sexual Health and HIV • British Association for the Study of the Liver (BASL) • British Association for the Study of the Liver Nurses Forum • British Geriatrics Society • British HIV Association • British Society for Gastroenterology • British Viral Hepatitis Group • Royal College of General Practitioners • Royal College of Nursing 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Drugs Action (Scotland) • Haemophilia Wales • Healthcare Improvement Scotland • Hepatitis Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • NHS Wales Joint Commissioning Committee • Scottish Medicines Consortium • Scottish Society of Gastroenterology • Welsh Government <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Aristo Pharma (entecavir) • Aurobindo Pharma (entecavir, tenofovir disoproxil) • Bristol Myers Squibb (entecavir) • Cipla (entecavir) • Dr. Reddy's Laboratories (tenofovir disoproxil) • Gilead Sciences (tenofovir disoproxil) • Glenmark Pharmaceuticals (entecavir) • Orion Pharma (tenofovir disoproxil) • Pharmaand (peginterferon alfa-2a) • Ranbaxy (entecavir) • Sandoz (tenofovir disoproxil)

Provisional stakeholder list for the evaluation of bepirovirsen for treating chronic hepatitis B ID6608
Issue date: March 2026

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Clinical Virology Network • UK Harm Reduction Alliance <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • Thornton & Ross (tenofovir disoproxil) • Viartis (tenofovir disoproxil) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • UCL Centre for Sexual Health & HIV Research • UK National Screening Committee <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These

Provisional stakeholder list for the evaluation of bepirovirsen for treating chronic hepatitis B ID6608
Issue date: March 2026

organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.